Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Random number generation from a self-chaotic broad-area VCSEL.

Optics letters·2026
Same author

Sex-specific analysis of early disease course and treatment in a German multiple sclerosis cohort.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

CSF Proteins Associated With Neuroaxonal Damage in Early Active Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Synchronization of complex spatio-temporal dynamics with lasers.

Light, science & applications·2026
Same author

Pain in multiple sclerosis: clinical phenotypes and therapeutic strategies - a narrative review.

Pain reports·2026

Related Experiment Video

Updated: Dec 30, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K

Targeting CD52 does not affect murine neuron and microglia function.

Erik Ellwardt1, Christina Francisca Vogelaar1, Carlos Maldet2

  • 1Focus Program Translational Neurosciences (FTN) and Immunology (FZI), Rhine Main Neuroscience Network (rmn(2)), Department of Neurology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

European Journal of Pharmacology
|January 22, 2020
PubMed
Summary
This summary is machine-generated.

Alemtuzumab

Keywords:
AlemtuzumabMicrogliaMultiple sclerosisNeuronsNeuroprotection

More Related Videos

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.3K
Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions
08:47

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Published on: July 26, 2024

3.4K

Related Experiment Videos

Last Updated: Dec 30, 2025

Murine Model of CD40-activation of B cells
12:24

Murine Model of CD40-activation of B cells

Published on: March 5, 2010

13.1K
Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility
07:54

Rapid and Refined CD11b Magnetic Isolation of Primary Microglia with Enhanced Purity and Versatility

Published on: April 13, 2017

10.3K
Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions
08:47

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Published on: July 26, 2024

3.4K

Area of Science:

  • Neuroimmunology
  • Immunotherapy
  • Multiple Sclerosis Research

Background:

  • Alemtuzumab, an anti-CD52 antibody, treats multiple sclerosis (MS) by targeting B and T lymphocytes.
  • Potential direct effects of alemtuzumab on central nervous system (CNS) cells remain unexplored.

Purpose of the Study:

  • To investigate the expression of CD52 in CNS cells (neurons, astrocytes, microglia).
  • To determine the direct impact of anti-CD52 treatment on CNS cells and neuronal function.

Main Methods:

  • CD52 expression analysis in murine neurons, astrocytes, and microglia (in vitro and in vivo).
  • Assessment of alemtuzumab's effects in experimental autoimmune encephalomyelitis (EAE) mouse model.
  • Evaluation of microglial morphology and function in organotypic hippocampal slice cultures.
  • Testing neuronal calcium levels and neuroprotection in excitotoxicity models.

Main Results:

  • CD52 is expressed in murine neurons, astrocytes, and microglia.
  • Alemtuzumab treatment induced lymphopenia and improved EAE symptoms.
  • CD52 blockade altered microglial morphology but not function.
  • No significant effects of anti-CD52 on baseline neuronal calcium or neuroprotection against excitotoxicity were observed.

Conclusions:

  • CD52 blockade does not appear to have a significant functional role in CNS neurons or microglia.
  • The therapeutic benefits of alemtuzumab in MS are likely mediated exclusively by peripheral immune mechanisms.